Navigation Links
Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
Date:6/28/2010

CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on September 1st 2010, two years after having been appointed CEO of the Pierre Fabre Group.

"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its success and I take this opportunity to thank Mr. Pierre Fabre, visionary founder, for having entrusted me with this important mission".

Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".

The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.

    About Pierre Fabre group :

    The Pierre Fabre Group, the second largest independent French
    pharmaceutical company and leader in the field of in-pharmacy
    dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D
    staff, and generates a turnover of EUR 1.8 billion.

    In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to
    R&D in four priority therapeutic areas in public health: oncology, central
    nervous system, dermatology, cardio-vascular/metabolism.

    To learn more about Pierre Fabre, please refer to
    http://www.pierre-fabre.com.

    Press Contact :

    Djamila Hazene-Kedjem
    djamila.hazene.kedjem@pierre-fabre.com
    +33(0)1-49-10-81-72 / +33(6)89-45-87-95



'/>"/>
SOURCE Groupe Pierre Fabre
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
2. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
3. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
4. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
5. Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests
6. Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
7. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
8. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
9. Indevus Announces Submission of New Drug Application
10. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
11. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)...  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
Breaking Medicine News(10 mins):